Virus-HIVPOLYVIHNCT07388394
Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75
A study testing interview with advanced practice nurse in people with Virus-HIV, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
Trial summary
Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. Read more about this study
- Who is it for?
- Ages 75 years and older
- Conditions the study is for
- Virus-HIV
- What is being tested?
- interview with advanced practice nurse
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 136 participants
- Where
- 1 siteFrance
- Study dates
- 28 Jan 2026to 31 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 75 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- HIV-positive
- Aged 75 or over
- Affiliated with the social security system
- Having expressed no objection to participating in the study
Who cannot join
- Refusal to participate
- Known severe cognitive impairment preventing the interview from being conducted
- Patient under guardianship or conservatorship
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Irit TOUITOU contact
France1 site, 1 recruiting
- Recruiting
CHU de NICE
Nice, CHU de Nice
Lysandre BLANCKEMAN, 04 92 03 54 67, Blanckerman.l@chu-nice.fr
Irit TOUITOU, Touitou.i@chu-nice.fr
About this study
Official title: Describe and Evaluate the Impact of Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75 Who Are Being Treated at Nice University Hospital.
Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, aims to improve the lives of older people. In this context, a study will be conducted at the Nice University Hospital among PLHIV aged 75 and over. It will collect quantitative data, the results of which will enable us to consider, if necessary, adapting the care pathways of these patients whose needs are complex.
- Conditions
- Virus-HIV
- Being tested
- interview with advanced practice nurse
- Medical subject headings
- Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
interview with advanced practice nurseOther
45 to 60 minutes of interview
| Study group | Role | What they receive |
|---|---|---|
| people living with HIV over the age of 75 | Other | Not described Receives: Other: interview with advanced practice nurse |
What is being measured
The primary outcome is the main question the study is designed to answer.
Describe polypharmacy among people living with HIV aged 75 and older.
The average number of medications taken
Measured: 18 months
Secondary outcomes (3)
Assess the most common comorbidities associated with polypharmacy in the population of PLHIV aged 75
Number et type of comorbidities
Measured: 18 months
Assess whether people taking multiple medications have a lower treatment adherence score than those taking fewer medications.
Score obtained on the Morisky MMAS-8 questionnaire
Measured: 18 months
Assess the level of functional independence in this age group and link it to the existence of polypharmacy.
Lawton and Brody IADL scale
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2026
- Study start28 Jan 2026
- Primary completion31 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Virus-HIVStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NiceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 136 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07388394
- Sponsor's protocol ID
- 25-PP-19
- Acronym
- POLYVIH
- Status last verified
- Oct 2026
- First submitted
- 19 Jan 2026
- Last updated
- 29 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Describe and Evaluate the Impact of Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75 Who Are Being Treated at Nice University Hospital.
- ClinicalTrials.gov ID
- NCT07388394
- Acronym / sponsor ID
- POLYVIH / 25-PP-19
- Conditions
- Virus-HIV
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 136 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de NiceUniversity, hospital or other
- Study start
- 28 Jan 2026 (actual)
- Primary completion
- 31 Aug 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 5 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, aims to improve the lives of older people. In this context, a study will be conducted at the Nice University Hospital among PLHIV aged 75 and over. It will collect quantitative data, the results of which will enable us to consider, if necessary, adapting the care pathways of these patients whose needs are complex.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| people living with HIV over the age of 75 | Other | Other: interview with advanced practice nurse |
Who may qualify
- Ages
- 75 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- HIV-positive
- Aged 75 or over
- Affiliated with the social security system
- Having expressed no objection to participating in the study
Key exclusion criteria (3 listed)
- Refusal to participate
- Known severe cognitive impairment preventing the interview from being conducted
- Patient under guardianship or conservatorship
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| interview with advanced practice nurse45 to 60 minutes of interview | Other | people living with HIV over the age of 75 |
Primary outcome
Describe polypharmacy among people living with HIV aged 75 and older.
Time frame: 18 months
The average number of medications taken
3 secondary outcomes
Assess the most common comorbidities associated with polypharmacy in the population of PLHIV aged 75
Time frame: 18 months
Assess whether people taking multiple medications have a lower treatment adherence score than those taking fewer medications.
Time frame: 18 months
Assess the level of functional independence in this age group and link it to the existence of polypharmacy.
Time frame: 18 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Virus-HIV
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Irit TOUITOU contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing interview with advanced practice nurse in people with Virus-HIV, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lysandre BLANCKEMAN (04 92 03 54 67, blanckerman.l@chu-nice.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Describe polypharmacy among people living with HIV aged 75 and older. (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.